The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past, Present, and Future Factors Involved in Embryo Implantation Success by López-Luna, Almena et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
The Genetic and Biochemical 
Blueprint of Endometrial 
Receptivity: Past, Present, and 
Future Factors Involved in Embryo 
Implantation Success
Almena López-Luna, Dinorah Hernández-Melchor, 
Leticia Ramírez-Martínez and Esther López-Bayghen
Abstract
In the field of assisted reproductive technology, endometrial receptivity is a 
crucial aspect that affects implantation rates in in-vitro fertilization procedures; 
in fact, impaired endometrial receptivity has been identified as the rate-limiting 
step for favorable pregnancy outcomes once factors regarding embryo quality have 
been optimized. The endometrium is a dynamic tissue that undergoes proliferative 
and secretory changes in each menstrual cycle, acquiring a short and transient 
period of embryo receptivity known as the Window of Implantation. Precise 
embryo-endometrial synchrony is necessary to achieve a successful pregnancy, 
and it involves complex and multifactorial processes related to morphological, 
biochemical, and genetic changes. On that behalf, defining the receptive window 
of each patient for personalized embryo transfer is a current goal. Here, we review 
different indicators of endometrial receptivity throughout the menstrual cycle, 
spotlighting the opening of the window of implantation: classical histological 
and biochemical markers, genetic factors, leading-edge transcriptomic signatures 
and miRNA profiles, and novel features such as the microbiome and secretome. 
Understanding the molecular mechanisms behind endometrial receptivity will 
facilitate the optimization and improvement of infertility treatments.
Keywords: endometrial receptivity, embryo implantation, menstrual cycle, window 
of implantation, decidualization
1. Introduction
The field of assisted reproductive technology (ART) has grown significantly in 
use and understanding over the past few decades, nevertheless, the rates of suc-
cessful pregnancies in in-vitro fertilization (IVF) procedures are still relatively low. 
Impaired endometrial receptivity (ER) has been identified as the rate-limiting step 
for favorable pregnancy outcomes once all other factors, including the acquisi-
tion and selection of the best quality embryo(s), have been optimized. Correct 
and synchronized maturation of the endometrial tissue is essential for embryo 
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implantation [1, 2]. The endometrium is a dynamic tissue that undergoes prolifera-
tive and secretory changes in each menstrual cycle. Throughout most of this cycle, 
the endometrium remains “non-adhesive” to embryos and it only acquires a short 
and transient period of embryo receptivity known as the “window of implantation” 
(WOI) [3, 4]. In humans, during a natural cycle, the endometrium becomes recep-
tive 6 to 8 days after ovulation and it remains receptive for approximately 24–48 
h, this time is assumed to occur between days 20 and 24 of a regular menstrual 
cycle [2, 5] (Figure 1). The cyclic fluctuations of the endometrium are coordinated 
by the ovarian hormones estrogen (E2) and progesterone (P4); a finely balanced 
signaling process mediated by these hormones defines the WOI. The menstrual 
cycle is divided in two phases: proliferative or follicular, and secretory or luteal 
[6]. During the proliferative phase (PP), E2 from the maturing follicle allows the 
elongation of the spiral arteries and the proliferation of endometrial stromal cells 
(EnSCs) and glands [7]. Afterwards, during the secretory phase (SP), P4 from the 
corpus luteum induces secretory changes; the endometrium thickens and it acquires 
a receptive phenotype that will support blastocyst attachment [8–10]. During the 
Mid-Secretory Phase (MSP) circulating P4 induces EnSCs to undergo decidualiza-
tion [11]. Decidualization is the transformation of the endometrial stroma into a 
dense cellular matrix known as the decidua, this process initiates during the SP 
in the stroma and, if pregnancy occurs, it progresses into the development of the 
decidua which will in turn form the maternal placenta [12]. The optimization of 
the endometrium to support embryo implantation is a complex and multifactorial 
process that involves morphological, biochemical, and genetic changes [13]. ER is a 
key aspect that affects implantation rates in IVF procedures considering that a pre-
cise embryo-endometrial synchrony is completely necessary to achieve a successful 
pregnancy [4, 14]. Thus, understanding the molecular mechanisms behind ER will 
facilitate the optimization and improvement of infertility treatments.
2. Factors involved in endometrial receptivity
2.1 Evaluation of endometrial morphology for receptivity assessment
Morphological changes during the endometrial cycle generate markers that have 
been used over decades to assess receptivity, such as histological evaluation of a biopsy 
and ultrasound examination of the endometrium. Endometrial biopsies are now 
Figure 1. 
Endometrial dynamics throughout the menstrual cycle. This picture was modified from Servier Medical Art 
under the Creative Commons License 2018.
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considered to provide little clinically relevant information [15, 16]. Additionally, the 
formation of pinopodes was thought to show potential as a clinical marker to assess 
ER [17]. However, the presence of pinopodes was demonstrated not only during the 
WOI but also in the post-receptive endometrium, precluding in this way its use as 
a marker of ER [17, 18]. On the other hand, ultrasound examination is a routinely 
used technique in IVF procedures [9, 19]. This non-invasive technique is based on the 
interpretation of a medical ultrasound of the endometrium. Various ultrasonographic 
parameters have been proposed as pregnancy predictors, such as endometrial thick-
ness, volume, and blood flow patterns. The most commonly used is endometrial thick-
ness [20, 21]. Due to differences in stimulation protocols, sonographic approaches, 
and difficulties in obtaining a standard sagittal view of the uterus, discrepancies in 
the cut-off value of endometrial thickness to achieve pregnancy arise [22]. Generally, 
it is considered that a minimum of 6–8 mm in endometrial thickness is necessary for 
a successful pregnancy [23–25]. Nevertheless, case reports have described pregnancy 
establishment despite an endometrial thickness of no more than 4 mm [26, 27]. Three-
dimensional (3D) sonography assesses ER by considering endometrial thickness, 
volume, and angiogenic dynamics. The endometrial volume of fewer than 2 ml has 
been shown to decrease pregnancy rates significantly [19, 28, 29]. Another evaluated 
criterion is an endometrial pattern, which can be classified as triple-line, intermediate, 
or homogenous [30]. Among these, the triple-line pattern has been suggested to reflect 
ER [24, 31] broadly. Finally, the impact of ovarian stimulation on ER has yet to be 
determined. Abnormal hormone concentrations the due to stimulation protocols dur-
ing IVF might affect endometrial morphology and thereby ER [32]. Comprehensively, 
although morphological elements are important components of receptivity, there is 
still no consensus on the extent in which they can be used as WOI predictors.
2.2 Genetic factors involved in ER
Endometrial genetic abnormalities can lead to implantation failure due to dys-
regulation of critical processes such as trophoblast invasion and angiogenesis. Here, 
we discuss common genetic abnormalities that have been analyzed to determine 
their role in implantation failure (Table 1). Parental chromosomal abnormalities 
such as mutations and translocations should be considered relevant in the efficacy 
of improving reproductive outcome.
2.2.1  Angiogenetic factors: vascular endothelial growth factor (VEGF), endothelial 
nitric oxide synthase (eNOS), TP53 tumor suppressor (TP53), murine double 
minute 2 (MDM2), herpes virus-associated ubiquitin-specific protease 
(HAUSP)
Successful pregnancy is dependent on adequate placental circulation and fetal 
vasculature. The development of a normal vascular network during implantation, 
embryo development, and placentation requires cooperation between different cell 
types and various growth factors. VEGF is a potent angiogenic factor that plays an 
essential role in embryo implantation/development. Four VEGF polymorphisms 
have been reported to affect VEGF activity and expression increasing aberrations 
in vascular formation and/or function. The polymorphism −1154G/A located in the 
promoter region has been associated with RPL [33], RSA [34, 35], and RIF [36, 37]. 
Moreover, a meta-analysis showed that genotypes −2578C/A, −634G/C, and 936C/T 
increase the risk of RSA as well [38]. Furthermore, eNOS, which is expressed in the 
terminal chorionic villous vessels, is important for vascular nitric oxide (NO) pro-
duction to supply nutrients to the fetus. Only the eNOS Glu298Asp polymorphism 
has been shown to be significantly associated with RPL [39]. Additionally, success-
ful trophoblast invasion requires the induction of paracrine apoptotic reactions to 
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Gene Polymorphism rs code Relevance References
APOE Heterozygous genotype is more frequent 
in women with RPL
[33]
eNOS VNTR (B/A) Association to the risk of RPL [77]
No associated [78]
Glu298Asp Homozygote genotype T/T is associated 
with risk of IRM
[39]
ESR1 IVS1-397T>C rs2234693 Related to unknown thin endometrium in 
which P allele may be the risk and X allele 
its guard factor
[44]
IVS1-351A>G rs9340799
F2 G20210A rs1799963 No association [58, 60, 62, 
63]
Heterozygous genotype is more frequent 
in women with RSA in the first trimester 
[57] and women with RPL [42]
[42, 57]
F5 G1691A, Leiden rs6025 No association [57, 58, 62, 
63]
More frequent in women with RIF [60]
H1299R (R2) No association [58, 62, 63]
Y1702C No association [58, 62, 63]
F8 V34L More prevalent in women with RPL [42, 58]
No association [62, 63]
FGB G-455A rs1800790 No association [57, 58, 62, 
63]
GPIIIa C1565T No association [57]
HAUSP rs1529916 G/A rs1529916 Allele A is associated with RIF [40]
HPA1 HPA1 a/b  
(L33P)
No association [58, 62, 63]
LIF C715A No associated [72]
G3400A More frequent in nulligravid women [72, 73]
G3424A No associated [72]
T1414G rs929271 G/G genotype is associated with RIF [40, 74]
MDM2 T309G rs2279744 Allele G is associated with RIF [40]
MTHFR A1298C rs1801131 No association [58, 62–64]
C677T rs1801133 More frequent in women with 
unexplained infertility [64], RPL [42, 
58], and RSA [60]
[42, 58–60]
No association [57, 62, 63]
MUC1 VNTR Women with unexplained infertility 
might have susceptibility to 
implantation failure due to small MUC1 
allele size
[67]
No association [68, 69]
MUC4 VNTR No association [70]
PAI-1 4G/5G rs1799889 More prevalent in women with RIF [63] 
and RPL [42, 58]
[42, 58, 63]
No association [62]
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secrete proteases capable of digesting the endometrial extracellular matrix (ECM) 
[36]. TP53 is a potent regulator of apoptosis, cell cycle, angiogenesis, and embry-
onic development. A TP53 polymorphism at codon 72, encoding either proline or 
arginine, was reported to alter the TP53 activity and affect human fertility [40]. 
The Arg72 variant has been shown to induce higher apoptotic activity than Pro72. 
Therefore, Pro72 variant might cause inadequate trophoblast invasion, increasing 
the risk of RPL [41] and RIF [37, 40]. In this manner, women with Pro/Pro genotype 
have a higher risk of RPL than women with the Arg/Arg or Arg/Pro genotypes. 
Following, MDM2 and HAUSP regulate TP53. MDM2 binds to TP53 to degrade it 
through poly-ubiquitination, blocking its ability to function as a transcription factor. 
The MDM2 SNP309 is a functional SNP that increases MDM2 expression levels and 
attenuates TP53 pathway. HAUSP, on the other hand, acts as a specific deubiquitinase 
for TP53, the A allele has a significant association with infertility in young patients 
(<35 years) but not in the older patients, similarly to the MDM2 SNP309 G allele. 
Those observations suggest that MDM2 and HAUSP may be involved in the regula-
tion of human fertility through the regulation of TP53 [40].
Gene Polymorphism rs code Relevance References
PR H770H-C/T No association [54]
G/T—Val660Leu rs1042838 More prevalent in women with 
unexplained infertility
[65]
V660L No association [54]
PT53 Codon 72 Pro rs1042522 Homozygote genotype is associated with 
RPL [41, 75], IRM [76] and RIF [37, 40]
[37, 40, 41, 
75, 76]
Codon 72 Arg rs1042522 Homozygote genotype is associated with 
RIF
[75]
PTGS2 G-765C rs20417 Association with implantation failure 
susceptibility
[55]
TFF3 rs225361 A/G rs11701143 Homozygous genotype is associated 
with less live births before their first 
spontaneous abortion
[61]
rs225361 A/G rs11701143 No association [66]
rs11701143 T/C rs225361 Associated with idiopathic RSA [61]
rs11701143 T/C rs225361 No association [66]
rs225439 G/A rs225439 No association [61, 66]
ros533093 C/T rs533093 No association [61, 66]
rs77436142 G/C rs7743614 No association [61, 66]
VEGF G-1154A rs1570360 Homozygote A/A genotype associated 
with RSA [34, 35], RPL [33], and RIF 
[36, 37]
[33–37]
No associated [71]
C-2578A rs699947 No associated [34]
G-634C rs2010963 No associated [34]
C936T rs3025039 No associated [34]
Probably implicated mutations in implantation failure, studies are listed even when no association was found, rs code 
is mentioned whenever it is reported.
Table 1. 
Genetic abnormalities involved in implantation failure.
Modern Medical Genetics and Genomics
6
2.2.2 Apolipoprotein E (APOE)
Due to the increase in total cholesterol levels during pregnancy, APOE plays a 
crucial role in lipid metabolism. APOE has three alleles in the long arm of chromo-
some 19 at position 13.2: ε2, ε3, and ε4. Individuals harboring the allele ε4 have 
higher cholesterol levels than the ones carrying the ε3/ε3 allele, whereas levels in 
those with the ε2 allele are lower [42].
2.2.3 Estrogen receptor α (ESR1)
ESR1 is a ligand-activated transcription factor essential for sexual development 
and reproductive function; its dysregulation leads to the development of various 
diseases such as cancer, cardiovascular disease, and inflammation, among others [43]. 
Due to alternative splicing of mRNA, it possesses three isoforms: ERαΔ3, ERα36, and 
ERα46 [43]; in a study performed by Yuan and Le [44], the polymorphisms rs2234693 
and rs9340799 were related to the uncommonly thin endometrium.
2.2.4 Leukemia inhibitor factor (LIF)
LIF is an important implantation factor that promotes proliferation, invasion, 
and differentiation; its expression is regulated by the transcription factor tumor 
protein TP53 (TP53). Few studies have found a correlation between LIF gene 
polymorphism and reproductive capacity, Kang et al. demonstrated that SNP in the 
3’UTR of the LIF (rs929271) gene is associated with infertility [40].
2.2.5 Mucin 1 (MUC1), Mucin 4 (MUC4)
MUC1 is an anti-adhesion molecule secreted by human endometrial epithelium, 
it has been suggested that its expression prevents the adherence of blastocyst to the 
endometrium. Interestingly, MUC1 must be locally removed in a paracrine fashion 
at the implantation site during the WOI to allow contact between the embryo and 
the endometrium, making it an important factor in determining ER [45–48]. MUC1 
is a highly polymorphic gene that differs in the size of the region carrying the 
O-glycosylation sites: the variable number tandem repeat region (VNTR), which 
can go from 20 to 125 repeats [49]. Similarly, MUC4 is a greatly expressed mucin in 
endometrial epithelium [50], its gene is highly polymorphic and it contains a VNTR 
region that can go from 145 to 395 repeats [51]. Although its role in human infertil-
ity has not been fully explored, studies in other species have suggested that it plays a 
role in embryo implantation [52, 53].
2.2.6 Progesterone receptor (PR)
The PROGINS complex are three mutations in the PR gene that may be associ-
ated with unexplained infertility and implantation failure: a 306 bp insert in intron 
G of the dT2 allele in PR, the mutated alleleV660L, and guanine to thymine substi-
tution in exon 4, resulting in a valine to leucine change in the hinge region of PR, 
and a cytosine to thymine substitution at exon 5 [54].
2.2.7 Prostaglandin-endoperoxide synthase 2 (PTGS2)
PTGS2 is a key enzyme involved in the conversion of arachidonic acid to prostaglan-
dins (PGs). The −765G>C SNP mutation in the promoter region of PTGS2 upstream 
the transcriptional start site in the putative Sp1 site can cause alterations in Sp1 binding 
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[55]. Accordingly, the hypermethylation of the NF-IL6 site within the PTGS2 promoter 
results in elevated gene expression in eutopic endometrium in endometriosis [56].
2.2.8  Thrombolytic factors: coagulation factor II (F2), coagulation factor V (F5), 
coagulation factor XIII a chain (F13A1), methylenetetrahydrofolate reductase 
(MTHFR), plasminogen activator inhibitor-1 (PAI-1)
Thrombophilia, the predisposition for thrombosis, has been shown to be a 
risk factor for successful pregnancy due to impaired vascularization at the time 
of implantation. Therefore, the possible association between early pregnancy loss 
and polymorphisms at coagulation factors and thrombolytic genes responsible for 
inherited or acquired thrombophilia has been investigated. The coagulation factor 
II SNP G20210A in the 3′-untranslated region of F2 causes elevated prothrombin in 
plasma, leading to enhanced blood coagulation [57]. Furthermore, factor V Leiden 
mutation, G1691A, is a single nucleotide substitution in the F5 gene that results in 
reduced clearance of factor Va due to its blocked inactivation by activated protein C, 
increasing the risk of thrombosis [42, 57]. Also, factor XIII V34L polymorphism is a 
guanine to thymine substitution in exon 2 of F13A1 that leads to a valine for leucine 
change in residue 34; this SNP leads to reduced susceptibility to fibrinolysis and 
influences fibrin degradation [57]. Moreover, MTHFR is the rate-limiting enzyme in 
the methyl cycle. C677T polymorphism causes a substitution of valine for alanine, 
resulting in a thermolabile variant of the enzyme with reduced catalytic activity; 
combined with the SNP AC1298C, it is associated with hyper-homocysteinemia, a 
risk factor for venous and arterial thrombosis [42, 58–60]. Additionally, PAI-1 is a 
key regulatory element in the fibrinolysis cascade, it is believed to control proteolysis 
and remodeling of maternal tissue during trophoblast invasion. The 4G/5G poly-
morphism is located 657 bp upstream from the start site of transcription within the 
PAI-1 promoter and results in an allele with decreased transcriptional activity [42].
2.2.9 Trefoil factor 3 (TFF3)
TFF3 is a mucin-associated peptide co-expressed in mucus cells that acts as a 
mitogen to promote epithelial cell migrations and mediates epithelial repair after 
damage. The SNP rs11701143 is located in the promoter region of TFF3 within the 
regulatory region of the transcription binding site, whereas rs225361 is an intron 
variant located within a regulatory region. The exact function of both SNPs remains 
to be elucidated [61].
2.3 Immunological factors contributing to ER
The immune system plays a major role in the process of implantation and preg-
nancy maintenance [62]. During decidualization, endocrine processes transform 
uterine fibroblasts into cells that can produce hormones, growth factors, and matrix 
components to support embryo implantation [63, 64]. Furthermore, tolerance of 
the immune maternal system is required in pregnancy to avoid rejection of the semi-
allograft or allograft embryo and for its successful implantation [65]. The decidua 
is a privileged site for immune tolerance; a large number of molecules and immune 
cell types participate in this process, leukocytes, macrophages, T lymphocytes, and 
dendritic cells comprise around 30 to 40% of the cells within the decidual stroma in 
early pregnancy. Among leukocytes, uterine natural killer (uNK) cells are activated 
and they significantly increase during decidualization (65–70%) [66, 67]. Increases 
in uNK cells denote three main functions in the endometrium: regulation of placental 
and trophoblast growth by cytokines [68, 69], local immunomodulation [70, 71], and 
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control of trophoblast invasion [69]. Furthermore, trophoblast cells play a major role 
in immune tolerance since these cells do not express major histocompatibility complex 
(MHC) class I (HLA-A and HLA-B) or class II molecules; ensuring that maternal T cells 
with αβ receptors cannot mount a classic cytotoxic attack against fetal paternal alloan-
tigens. The trophoblast also protects itself by expressing Fas ligand (Fas L), which is 
important in the elimination of maternal reactive T cells by apoptosis induction [72–74]. 
Other important component of this process is T-regulatory (Treg) cells; these cells are 
essential for immunosuppression, prevention of autoimmunity, and maternal tolerance 
to the fetus [75–78]. Treg cells have been shown to be locally enriched in decidua during 
early normal pregnancy [79]. Furthermore, Forkhead box P3 (Foxp3) is a master regu-
lator of Treg cell development, function, and differentiation [80]. Expression of FOXP3 
was reduced approximately two-fold in endometrial biopsies of infertile women, impli-
cating that the impaired differentiation of uterine T-cells into the Treg phenotype is a 
key determinant of fertility [81, 82]. On the other hand, helper T cells (CD4+) facilitate 
embryo implantation by regulating endometrial differentiation; they secrete inter-
leukins and interferons that establish the implantation microenvironment. Successful 
pregnancy is dependent upon Th1/Th2 balance [83]. While Th1 cytokines are harmful 
for pregnancy, Th2 cytokines favor fetal growth and regulate uterine expression of 
fatty acid amide hydrolase (FAAH), LIF, and trophoblast release of human chorionic 
gonadotropin (hCG), which are known to play important roles during implantation 
[84–86]. Piccinni et al. demonstrated that T cells from decidua of women with a miscar-
riage show predominantly Th1-type cytokines with decreased Th2-type [84, 87, 88]. 
Finally, P4 and E2 mediate the downregulation of the maternal immune system [89]. P4 
stimulates decidual proliferation; therefore, pregnancy results in an upregulation of P4 
receptors on activated lymphocytes among placental cells and decidual CD56+ cells. In 
the presence of sufficient P4, these cells express progesterone-induced blocking factor 
(PIBF), a mediator that exerts substantial anti-abortive activities.
2.4 Biochemical markers involved in ER
We review molecular markers involved in the decidualization process that could 
be suitable as makers to assess ER.
2.4.1 Homeobox A10 (HOXA10)
HOXA10 is a transcription factor member of the homeobox family, known to be 
involved in the genetic control of embryonic development and in the regulation of 
the adult female reproductive tract [12, 90]. HOXA10 regulates downstream target 
genes that lead to endometrium development and receptivity acquisition [91], such as 
insulin-like growth factor binding protein 1 (IGFBP1) [12, 92, 93], genes of the Wnt 
pathway (reviewed by Sonderegger et al. [94], integrin β3 (ITGB3) [12, 90, 92], and 
empty spiracles homolog 2 (EMX2) [12, 95]. HOXA10 is regulated by P4 in a dose-
dependent manner [12, 90, 91]. The expression of HOXA10 is low during the PP and 
it rapidly increases in the MSP [12, 90]. The diminished expression of HOXA10 in 
endometria of women with recurrent pregnancy loss (RPL) [96], adenomyosis [97], 
endometriosis [92], polycystic ovary syndrome (PCOS) [98], and idiopathic infertil-
ity [99] indicates that this gene could be essential for fertility [12].
2.4.2 Heparin-binding epidermal growth factor-like growth factor (HB-EGF)
HB-EGF is a member of the epidermal growth factor (EGF) family, it is 
expressed in the human uterus at the time of implantation and its expression is 
under steroidal hormone control [100–103]. The transmembrane form is associated 
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with cell adhesion and migration, it allows communication with the blastocyst by 
acting as a chemoattractant [101, 104]. HB-EGF expression is low in the PP and 
increases in the ESP immediately prior to the WOI, after which its levels decrease 
[101–103, 105]. Also, mRNA levels are low in pregnant endometrium and high in 
placental tissues at an early stage of development, suggesting that the HB-EGF 
ligand not only potentiates the health and survival of the peri-implantation 
embryo, but also induces the progression of its development [104]. HB-EGF stimu-
lates epithelial expression of key endometrial proteins that are important biomark-
ers of the WOI, including LIF, HOXA10, and ITGB3 [100].
2.4.3 Leukemia inhibitory factor (LIF)
LIF is a member of a cytokine family with functional redundancy that includes 
interleukin 6 (IL6), oncostatin (OSM), ciliary neurotrophic factor (CNTF), and 
cardiotrophin 1 (CT1). They regulate proliferation, differentiation, and cell sur-
vival in different cellular systems [106]. LIF acts on cells by binding to the heterodi-
meric LIF receptor (LIFR), which consists of two transmembrane proteins, LIFR 
and glycoprotein 130 (gp130). LIFR activates several signaling pathways including 
the JAK/STAT, MAPK, and P13-kinase pathways, whereas gp130 participates in the 
activation of STAT1, STAT3, and STAT5B [107]. LIF induces the expression of cyto-
kines and other regulatory molecules that could serve to regulate preimplantation 
development and embryo implantation [106–108]. LIF is one of the most important 
cytokines for receptivity during the WOI, the expression of LIF and LIFR reaches 
its highest level during the WOI in the MSP, LSP, and in early pregnancy in both 
surface and glandular epithelial cells under the influence of P4 [106, 107, 109, 110]. 
LIF can also be detected in decidual leukocytes, which are abundant at the implan-
tation site; interestingly, LIF expression is low in women with unexplained infertil-
ity [106, 107, 111]. LIF also plays a crucial role in the regulation of fetal-maternal 
interactions during pregnancy, this cytokine mediates uterine receptivity through 
autocrine/paracrine interactions by binding to LIFR on the luminal epithelium to 
permit blastocyst attachment [106], but also regulates trophoblast function and 
vascular formation in the placenta [109].
2.4.4 Integrin β3 (ITGB3)
Integrins are ubiquitous cell adhesion molecules involved in maintaining nor-
mal tissue morphology and participate in cell–cell and cell-substrate interactions 
[100, 110, 112, 113]. In the human endometrium, integrins are involved in early 
embryo-endometrial interactions [90]. ITGB3 subunit is present after the ESP 
and its expression extend into the pregnancy [112, 114]. It has been reported that 
healthy fertile women show higher ITGB3 expression than patients with unexplained 
infertility [46, 96, 113–115]. Moreover, its dysregulation appears to characterize two 
distinct pathophysiological conditions that involve distinct mechanisms of defective 
ER: Type I and Type II. Type I defect is an out-of-phase endometrium with negative 
ITGB3 subunit expression, portrays a shifted WOI, and hormonal inadequacy or 
responsiveness is implicated, on the other hand, Type II defect is an “in-phase” endo-
metrium with negative ITGB3 subunit expression and connotes the complete loss of 
the WOI. Furthermore, ITGB3 is expressed in EnSCs and endometrial glands with 
the highest levels in the MSP to LSP, suggesting a role in the regulation of endome-
trial function and implantation [115, 116]. Due to its temporal distribution and the 
effects of implantation when it is not present, ITGB3 is a useful molecular marker to 
assess ER. ITGB3 is regulated in the endometrium through a molecular mechanism 
via sex steroid signaling where HOXA10 acts as an intermediary [90, 96].
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Other identified markers that are important for decidualization in the human endo-
metrium include PR, particularly its encoded isoform progesterone receptor A (PR-A), 
homeobox A11 (HOXA11), PTGS2, MUC1, and interleukin 11 receptor (IL11R) [12].
2.5 Transcriptomic signature to determine the WOI
Microarray technology has been widely used to determine the transcriptomic 
profile of the endometrium by analyzing the expression of large batches of genes at 
different stages of the menstrual cycle. The most representative and commercially 
available test in this regard is perhaps the Endometrial Receptivity Array (ERA), 
developed in 2009 by Diaz-Gimeno et al., this test identifies the unique transcrip-
tomic signature of the receptive endometrium by analyzing 238 differentially 
expressed genes, predicting the WOI for personalized embryo transfer (pET) [108]. 
Various research groups have analyzed changes in gene expression during the differ-
ent phases of the endometrial cycle using microarray-based technologies [117–120], 
however, due to differences on results, unanimity about the main genes to be analyzed 
to determine the WOI has not been reached. Factors that contribute to the disagree-
ment among studies results include differences on experimental design, utilized 
probes, sample acquisition day, sample size, collection method, and the application 
of distinct statistical analyses. Nevertheless, some genes have been reported to be 
expressed similarly in more than one work, here, we present a compilation of the 
expression profiles of those candidate genes in the human endometrium (Table 2).
2.6 miRNAs involved in ER
Micro-RNAs (miRNAs) are small, single-stranded, non-protein-coding RNA 
sequences of ~18–25 nucleotides in length that play an important post-transcrip-
tional regulatory role in gene expression [121, 122] by targeting mRNAs for cleavage 
or transcriptional repression [123]. More than two decades have passed since the 
initial discovery of miRNAs in Caenorhabditis elegans by Lee et al. [124]; since then, 
great progress has been made in the understanding of miRNAs: what they are, 
how are synthesized, how regulate gene expression, and how they are involved in 
the formation and progression of pathological disorders. Extracellular miRNAs 
have been ubiquitously detected in body fluids [125]. Therefore, the presence and 
stability of miRNAs in biological fluids have advocated their potential as non-
invasive biomarkers. Nevertheless, the identification of reliable miRNA biomarkers 
with reproducible profiles has been a challenge, and their diagnostic promise has 
remained a work in progress since they have still not entered the clinical field [126]. 
Nonetheless, given that miRNAs are differentially expressed in the endometrium 
across the menstrual cycle [127–131], several studies have been conducted to 
explore their role in ER [131–136]. Table 3 presents a summary of these studies.
2.7 The endometrial secretome as a potential tool to ascertain ER
The aim to develop alternative non-invasive strategies to provide accurate 
receptivity assessment has drawn assiduity to the endometrial secretome, which is 
based in the identification of factors secreted by cells or tissues at a particular time 
in either physiological states or pathological conditions [137], including proteins, 
lipids, and metabolites. Therefore, the analysis of differentially present molecules 
in the uterine cavity at different time points of the menstrual cycle could potentially 
help to identify the WOI and to diagnose uterine pathologies. Sample collection of 
endometrial fluid (EF) collection in the peri-implantation period is an easy pro-
cedure performed with minimally invasive tools that could easily be implemented 
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Gene Functional category Expression profile References
Annexin 4 [ANX4] Apoptosis PP to MSP
ESP to MSP
MSP to LSP
↑
↑
↓
[73, 86, 91–95]
Apolipoprotein D [APOD] Cholesterol transport and 
trafficking
PP to ESP
ESP to MSP
↑
↑
[85, 92, 96]
Claudin 4 [CLDN4] Cell adhesion ESP to MSP ↑ [73, 85, 93, 94, 
96, 97]
Decay-accelerated factor 
[DAF]
Immune modulators/
cytokines
ESP to MSP ↑ [85, 93, 94, 98]
Dickkopf-1 [DKK1] Regulation of WNT signaling 
pathway
PP to ESP
ESP to MSP
ESP to LSP
↑
↑
↓
[73, 85, 92, 94, 
96, 97, 99]
Endothelin 3 [EDN3] Vasoactive substances ESP to MSP ↓ [73, 92, 93, 
100]
Growth arrest and DNA-
damage-inducible protein 
[GADD45]
Cell cycle PP to MSP
ESP to MSP
MSP to LSP
↑
↑
↑
[73, 92–94, 97, 
101]
Glutathione peroxidase 3 
[GPX3]
Response to stress and 
oxidoreductase activity
ESP to MSP ↑ [73, 86, 96]
Homeobox A10 [HOXA10] Transcription factor ESP to MSP
MSP to LSP
↑
↑
[55, 64, 94, 102, 
103]
Inhibitor of DNA binding 
4, dominant negative helix–
loop helix protein [ID4]
Anatomical structure 
development
ESP to MSP ↑ [73, 92–94, 
104]
Insulin-like growth factor 
binding protein 1 [IGFBP-1]
Anatomical structure 
development
ESP to MSP
MSP to LSP
↑
↑
[73, 94]
IL15 precursor [IL15] Immune response ESP to MSP ↑ [73, 85, 92–94, 
96]
Mitogen-activated protein 
kinase kinase kinase 5 
[MAPKKK5]
Signal transduction PP to ESP ↑ [92, 101]
Matrix metalloproteinase 26 
[DAMMP26]
Tissue remodeling and 
blastocyst invasion
MP to LPP
PP to ESP
MSP to LSP
↑
↑
↓
[87, 94]
[73]
Msh homeobox homologs 
1,2 [MSX1]
Anatomical structure 
development
ESP to MSP ↓ [73, 88, 91, 93, 
96]
Natural cytotoxicity-
triggering receptor 3 
[NCR3]
Immune response ESP to MSP
MSP to LSP
LSP to MP
MP to PP
↑
↑
↑
↓
[86, 87]
Olfactomedin 1 [OLFM1] Anatomical structure 
development
PP to ESP
ESP to MSP
↓
↓
[73, 88, 92, 93]
Sex-determining region 
Y-box 4 [SOX4]
Apoptotic pathways PP to ESP
MSP to LSP
MP to LPP
↓
↑
↑
[87, 88]
Osteopontin [SPP1] Cell adhesion PP to SP
ESP to MSP
↑
↑
[73, 85, 91–93, 
96, 97, 101]
Tissue inhibitor 
metalloproteinase 3 
[TIMP-3]
Degradation of the 
extracellular matrix
PP to ESP
ESP to MSP
MSP to LSP
↑
↑
↑
[73, 94, 95]
Genes expressed in human endometrium and its expression profiles at the different phases of the endometrial cycle. A 
compilation of the genes exhibiting the same expression profile in more than one work is presented, regardless of the 
differences among studies.
Table 2. 
Expression profiles of genes involved in ER.
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Reference and 
relevance
Methodology Results Targets
[132]
Shows distinct 
miRNA profiles 
in LPP and MSP
Samples: Endometrial 
biopsies LPP [n = 4] 
and MSP [n = 4]
Technique: 
Microarray 
Technology
49 differentially expressed 
miRNAs: 12 ↑ in the MSP 
[miR-214, 503, 134, 450, 
382, 376A, 369-5p, 222, 370, 
542-3p, 105, and 127] and 12 
↓ in LPP [miR-210, 193a-3p, 
345, 29b, 29c, 30b, 204, 203, 
582-5p, 30d, 200c, and 31]
Predicted: Cell cycle 
pathways in the LPP. Wnt 
signaling pathway in the 
PP. Validated: Decreased 
transcripts of predicted 
targets [cyclins, CDKs, and 
E2F3]
[134]
Evaluates 
differentially 
expressed 
miRNAs in RIF-
IVF patients
Samples: Secretory 
endometrium; 12 
fertile women versus 
11 women with RIF
Technique: TaqMan 
miRNA array cards
13 differentially expressed 
miRNAs:
10 ↑ [miR-23b, I45, 99a, 27b, 
652, 139-5p, 195, 342-3p, 150, 
and 374b] and 3 ↓ [miR-32, 
628-5p, and 874]
Predicted: Wnt signaling, 
adherents junctions, p53 
signaling, cell adhesion, 
and cell cycle pathways. 
Validated: Decreased 
transcripts of N-cadherin, 
H2AFX, NTN4, and 
SFRP4. Wnt and cell cycle 
pathways ↓ in RIF-IVF
[154]
Makes 
comparison 
between natural 
vs. stimulated 
cycles. Suggests 
that ovarian 
stimulation may 
shift the WOI
Samples: Infertile 
women. Receptive 
[LH + 7, n = 5] vs. 
prereceptive [LH + 2, 
n = 5] in natural cycles. 
Receptive [hCG + 7, 
n = 5] vs. prereceptive 
[hCG + 4, n = 5] in 
stimulated IVF cycles
Technique: Next-gen 
seq., 626 miRNAs 
evaluated
20 differentially expressed 
miRNAs in natural cycles: 8 
↑ [miR-30d, 30b, 30b, 31, 21, 
193a-5p, 193a3p, 203] and 
12 ↓ [miR-33a, 452, 125b, 
455-3p, 455-5p, 483-5p, 143, 
100, 504, 424, 424, 503]. 
22 differentially expressed 
miRNAs in stimulated cycles: 
19 ↑ [miR-187, 708, 433, 320a, 
320b, 34c-5p, 320c, 320d, 485-
5p, 574-5p, 375, 23b, 423-5p, 
193b, 34b, 503, 424, 455-5p, 
483-5p] and 3 ↓ [miR-886-5p, 
let-7f, let-7a]
Predicted: Cell cycle, 
transport, cell adhesion, 
cell death, and metabolism
[136]
Provides 
miRNA 
signature of 
EnSCs during 
decidualization 
in vitro
Samples: Endometrial 
samples on oocyte 
retrieval day from 
healthy ovum donors 
[n = 50]. EnSCs 
[n = 20] isolated and 
cultured
Technique: miRNA 
PCR array, 704 
miRNAs + specific 
miRNA-200b primers 
evaluated
43 differentially expressed 
miRNAs: 26 ↑ [miR-95, 888, 
936, 1185, 518f, 548 k, 593, 
486-5p, 29c, 449b, 300, 371-
5p, 1224-3p, 891a, 365, 541, 
409-5p, 33b, 154, 376a, 133a, 
218–2, 22, 614, 369-3p, 185] 
and 17 ↓ [miR-146a, 155, 
181b, 181a, 135b, 181d, 200c, 
141, 182, 429, 483-3p, 200a, 
96, 183, 9, 30a, 126]
miR-95 ↑ by P4 and E2 + P4; 
miR-96 and miR-135b both ↓ 
by E2 or P4
Predicted: Growth 
factors, interleukins, ECM 
remodeling enzymes.
• Top pathways by ↓ 
miRNAs: axon guidance, 
adherents junction, actin 
cytoskeleton regulation, 
ErbB [EGFR] signaling, 
and renal cell carcinoma.
• Top pathways by ↑ 
miRNAs: actin cytoskel-
eton regulation, adherent 
junction, axon guidance, 
Wnt signaling, and MAPK
[133]
Provides 
miRNA 
signature of 
fertile human 
endometria: 
receptive vs. 
prereceptive
Samples: Receptive 
MSP [LH + 7, n = 4] 
vs. prereceptive 
ESP [LH + 2, n = 5] 
endometrial biopsies 
from 9 healthy fertile 
women
Technique: 
Microarray, 723 
human and 76 
human viral miRNAs 
evaluated
4 significantly expressed 
different miRNAs in receptive 
samples: 2 ↑ [hsa-miR-30b and 
30d] and 2 ↓ [hsa-miR-494 
and 923]
Suggests 12 genes that could 
serve as a new panel for ER: 
CAST, CFTR, DPYSL2, FI IR, 
FGFR2, LIF, MTFI, NPAS2, 
P4HA2, PPARGCIA, TACC2, 
RAB40B
Predicted: Transcription, 
cell proliferation, and 
apoptosis. Involvement 
in pathways such as axon 
guidance, Wnt/β-catenin, 
ERK/MAPK, TGF-β, p53 
and leukocyte extravasation.
They identified SEPT7, 
CRMP1, SLC44A1, HES1, 
FXR2, and TNF144B as 
genes that interact with 
genes MIR30B and MIR30D
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in ART procedures. Proteomics of EF has already rendered valuable information 
regarding ER; Casado-Vela et al. identified 803 proteins in EF aspirates using three 
different proteomic strategies [138]. Additionally, Boomsma et al. [139] analyzed 
endometrial secretions prior to embryo transfer from 210 women undergoing IVF 
to determine differences in cytokine profiling at the time of implantation, finding a 
negative and a positive association of monocyte chemo-attractant protein-1 (MCP-1) 
and IFN-γ-inducible 10 kDa protein (IP-10) levels and implantation, respectively. 
Lipidomics, on the other hand, seems to have rendered slight information on 
receptivity [140], nevertheless, a study performed by Berlanga et al. [141] and fol-
lowed by Vilella et al. [142, 143] carried out lipidomic analyses of EF from patients 
at different stages of their menstrual cycle, they determined a significant increase in 
Prostaglandin E2 (PGE2) and Prostaglandin F2α (PGF2α) between days 19 and 21, 
coincident with the WOI. In a recent study performed by Durairaj, Aberkane et al. 
[144], the contribution of EnSCs to failed implantation was examined by analyzing 
the secretome profile of EnSCs cultures in-vitro. From there, they encountered that 
secretome profiles of pregnant women are less divergent in implantation-positive-
cultures particularly in Day 0 (undifferentiated cells), suggesting that endometrial 
defects linked to reproductive failure could be more prominent in the PP, a phase 
that is commonly thought to be not relevant for ER studies. This research group also 
demonstrated that the secretome of undifferentiated EnSCs compromises blastocyst 
development. Finally, they determined that a deficiency of endometrial mesenchy-
mal stem-like cells (MSCs) could lead to aberrant EnSC function and implantation 
failure. Overall, this study remarks the importance of progenitor cell populations in 
Reference and 
relevance
Methodology Results Targets
[130]
Differential 
miRNAs across 
cycle. Release 
of miRNAs into 
the EF and its 
uptake by the 
embryo
Samples: EF [n = 20] 
at different phases of 
the menstrual cycle 
of healthy women. 
Timing of sample 
collection: EPP, LPP, 
ESP, WOI, and LSP
Technique: 
Microarray, 866 
miRNAs evaluated
Compared with the WOI, 
9 differentially expressed 
miRNAs were identified in the 
EPP, 8 in the LPP, 6 in the ESP 
and 4 in the LSP.
MiR-30d was the most 
differentially secreted 
maternal miRNA in the EF 
during the WOI
Predicted: Cell cycle and 
endocrine processes
[135]
Shows a 
significant 
different 
expression of 
miRNAs in the 
WOI of RIF 
patients that 
may contribute 
to impaired ER
Samples: Endometrial 
biopsies from the 
WOI [5–7 days after 
ovulation]: 7 from 
RIF group and 5 from 
control group [infertile 
patients that delivered 
after one transfer 
attempt]
Technique: 
Microarray 
Technology
With a 2-fold threshold: 105 
miRNAs were differentially 
expressed: 93 ↑ and 12 ↓.
After raw signal value 
correction, 15 were found to 
be significantly different. 10 
↑ [hsa-miR-374a-5p, 145-5p, 
30b-5p, 196b-5p, 199a-5p, 
199b-5p, 449a, 424-5p, 
125b-5p, 21-5p] and 5 ↓ 
[hsa-miR-1207-5p, 4306, 572, 
5739, 6088]
Predicted: TAM analysis: 
miR-30 family, human 
embryonic stem cell 
regulation, epithelial-
mesenchymal transition, 
and miRNA tumor 
suppressors. Network 
regulatory analysis: 176 
miRNA-mRNA interactions. 
The top core mRNA 
were ABP1, AQP3, ASS1, 
and TIMP3, the top core 
miRNAs were has-miR-
4668-5p, 429, and 5088
Studies conducted to analyze miRNA expression profiles during the menstrual cycle as potential biomarkers of the 
WOI. A summary of the differentially expressed miRNAs and predicted targets found in recent studies is presented. Its 
relevance regarding the role of miRNAs is also addressed.
Table 3. 
Studies of miRNA-profiling during the WOI.
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the endometrium that supports the acquisition of receptivity and raises the prospect 
of screening the endometrium before the initiation of an ART procedure.
2.8 The microbiome as a novel aspect of ER
Historically, the uterus was assumed to be free of bacteria as the fetal envi-
ronment was considered to be physiologically sterile [145], this notion implies 
that the neonate’s microbiome is acquired only during and after birth. Although 
recent research still supports this conception [146], others have characterized 
upper genital tract microbiota [147–150], suggesting that the endometrial and 
vaginal microbiota not be identical [151]. What is more, the study by Moreno et al. 
[147, 152], which defined the microbiota in the EF as Lactobacillus-dominated (LD) 
or non-Lactobacillus-dominated (NLD), suggested that the presence of an NLD 
microbiota in a receptive endometrium was associated with a significant decrease 
in implantation, pregnancy, ongoing pregnancy, and live birth rates. Nevertheless, 
they acknowledge that in the absence of pathological signs, an NLD microbiota 
could be considered normal since Lactobacillus-deficient communities have been 
identified in the genital tract of otherwise healthy asymptomatic women [153]. This 
conception sets the stage for further research of the human microbiome, expands 
the possibilities to assess individualized receptivity based on the endometrial 
microbiome, and opens the door to explore targeted therapies for an altered endo-
metrial microbial habitat.
3. Remarks
This review encloses different aspects of ER, spotlighting the opening of the 
WOI. Altogether, this compilation could aid in the development of new clinical 
practices that define an individual’s receptive window for pET to improve ART 
results ultimately.
Nowadays, ER is the rate-limiting step in successful ART procedures that end 
up in pregnancy and child delivery. The endometrial tissue is a ponderous element 
in fertility; it constitutes the soil in which a viable embryo will implant to achieve 
progeny. The attainment of ER involves an extensive assortment of genetic and 
biochemical mechanisms that must integrate in a parallel manner. Understanding 
of this process as an entity is still insufficient; nevertheless, the surge of new 
technologies is contributing in the deciphering of receptivity mechanisms and in 
search of novel biomarkers that could serve to detect the WOI. Notably, although 
most studies focus on individual genetic mutations, a more comprehensive view of 
the parental genetics is needed to determine whether an endometrium is adequate 
for embryo transfer before the initiation of an ART procedure. Due to ambiguous 
or non-conclusive results in search of genetic predispositions of endometrial-
associated infertility, it would be controversial to provide genetic counseling 
currently. Perhaps, in the future, massive sequencing could help to provide insights 
into the importance of single and multiple genetic mutations to establish a receptive 
or non-receptive profile. If assertive, this profile could be applied as an endometrial 
pre-implantation parental test to improve the rates of healthy pregnancies and live 
births. With this in mind, in our opinion, the best short-term approaches towards 
detecting or improving ER are the transcriptome, microbiome, and miRNA signa-
tures, all achievable using the power of NGS. This review encloses different aspects 
of ER, spotlighting the opening of the WOI. Altogether, this compilation could aid 
in the development of new clinical practices that define an individual’s receptive 
window for pET to improve ART results ultimately.
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Abbreviations and nomenclatures
3D three-dimensional
ApoE apolipoprotein E
ART assisted reproductive tech
CNTF ciliary neurotrophic factor
CT1 cardiotrophin 1
E2 estrogen
ECM extracellular matrix
EF endometrial fluid
EGF epithermal growth factor
EMX2 empty spiracles homolog 2
eNOS endometrial nitric-oxide synthase
EnSCs endometrial stromal cells
EPP early-proliferative phase
ER endometrial receptivity
ERA endometrial receptivity array
ESP early-secretory phase
ESR1 estrogen receptor 1
F13A1 coagulation factor XIII A chain
F2 coagulation factor II
F5 coagulation factor V
F8 coagulation factor 8
FAAH fatty acid amide hydrolase
Fas L Fas ligand
FGB β fibrinogen
Foxp3 Forkhead box P3
gp130 glycoprotein 130
GPIIIa glycoprotein IIIa
HAUSP herpesvirus-associated ubiquitin-specific protease
HB-EGF heparin-binding epithermal growth factor-like growth factor
hCG human chorionic gonadotropin
HOXA10 homeobox A10
HOXA11 homeobox A11
HPA1 human platelet alloantigens 1
HSCORE histological score
IGFBP1 insulin-like growth factor binding protein 1
IL11R interleukin 11 receptor
IL6 interleukin 6
IP-10 IFN-γ-inducible 10 kDa protein
ITGB3 integrin β3
IVF in-vitro fertilization
LD lactobacillus-dominated
LH luteinizing hormone
LIF leukemia inhibitory factor
LIFR leukemia inhibitory factor receptor
LPP late-proliferative phase
LSP late-secretory phase
MCP-1 monocyte chemo-attractant protein-1
MDM2 murine double minute 2
MHC major histocompatibility complex
MiRNA microRNA
MP menstrual phase
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MSCs mesenchymal stem-like cells
MSP mid-secretory phase
MTHFR methylenetetrahydrofolate reductase
MUC1 Mucin 1
MUC4 Mucin 4
NGS next generation sequencing
NLD non-lactobacillus-dominated
OSM oncostatin
P4 progesterone
TP53 tumor protein 53
PAI-1 plasminogen activator inhibitor-1
PCOS polycystic ovarian syndrome
PCR polymerase chain reaction
pET personalized embryo transfer
PGE2 prostaglandin E2
PGF2α prostaglandin F2α
PGs prostaglandins
PIBF progesterone-induced blocking factor
PP proliferative phase
PR progesterone receptor
PR-A progesterone receptor A
RIF repeated implantation failure
RPL recurrent pregnancy loss
RSA recurrent spontaneous abortion
SNP single-nucleotide polymorphism
SP secretory phase
TAM tool annotations human miRNAs
TFF3 trefoil factor 3
Treg T-regulatory cells
uNK uterine natural killer
VEGF vascular endothelial growth factor
VNTR variable number tandem repeats
WOI window of implantation
17
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past, Present, and Future…
DOI: http://dx.doi.org/10.5772/intechopen.80452
Author details
Almena López-Luna1,2, Dinorah Hernández-Melchor1,2, Leticia Ramírez-Martínez2 
and Esther López-Bayghen2*
1 Laboratorio de Investigación y Diagnóstico Molecular, Instituto de Infertilidad y 
Genética SC, INGENES, Mexico
2 Departamento de Toxicología, Cinvestav-IPN, Ciudad de México, Mexico
*Address all correspondence to: ebayghen@cinvestav.mx
18
Modern Medical Genetics and Genomics
[1] Lessey BA. The role of the 
endometrium during embryo 
implantation. Human Reproduction. 
2000;15(Suppl 6):39-50
[2] Diedrich K et al. The role of the 
endometrium and embryo in human 
implantation. Human Reproduction 
Update. 2007;13(4):365-377
[3] Strowitzki T et al. The human 
endometrium as a fertility-determining 
factor. Human Reproduction Update. 
2006;12(5):617-630
[4] Teh WT, McBain J, Rogers P. What is 
the contribution of embryo-endometrial 
asynchrony to implantation failure? 
Journal of Assisted Reproduction and 
Genetics. 2016;33(11):1419-1430
[5] Achache H, Revel A. Endometrial 
receptivity markers, the journey to 
successful embryo implantation. 
Human Reproduction Update. 
2006;12(6):731-746
[6] Reed BG, Carr BR. The normal 
menstrual cycle and the control of 
ovulation. In: De Groot LJ et al., editors. 
South Dartmouth (MA): Endotext; 2000
[7] Cha J, Sun X, Dey SK. Mechanisms 
of implantation: Strategies for 
successful pregnancy. Nature Medicine. 
2012;18(12):1754-1767
[8] Mahajan N. Endometrial receptivity 
array: Clinical application. Journal 
of Human Reproductive Sciences. 
2015;8(3):121-129
[9] Heger A, Sator M, Pietrowski 
D. Endometrial receptivity and its 
predictive value for IVF/ICSI-outcome. 
Geburtshilfe und Frauenheilkunde. 
2012;72(8):710-715
[10] Beier HM, Beier-Hellwig 
K. Molecular and cellular aspects 
of endometrial receptivity. 
Human Reproduction Update. 
1998;4(5):448-458
[11] Lockwood CJ et al. The role of 
decidualization in regulating endometrial 
hemostasis during the menstrual cycle, 
gestation, and in pathological states. 
Seminars in Thrombosis and Hemostasis. 
2007;33(1):111-117
[12] Lu Z, Hardt J, Kim JJ. Global analysis 
of genes regulated by HOXA10 in 
decidualization reveals a role in cell 
proliferation. Molecular Human 
Reproduction. 2008;14(6):357-366
[13] Jabbour HN et al. Endocrine 
regulation of menstruation. Endocrine 
Reviews. 2006;27(1):17-46
[14] Fox C et al. Local and systemic 
factors and implantation: What is 
the evidence? Fertility and Sterility. 
2016;105(4):873-884
[15] Murray MJ et al. A critical analysis 
of the accuracy, reproducibility, and 
clinical utility of histologic endometrial 
dating in fertile women. Fertility and 
Sterility. 2004;81(5):1333-1343
[16] Coutifaris C et al. Histological 
dating of timed endometrial biopsy 
tissue is not related to fertility 
status. Fertility and Sterility. 
2004;82(5):1264-1272
[17] Nikas G. Endometrial receptivity: 
Changes in cell-surface morphology. 
Seminars in Reproductive Medicine. 
2000;18(3):229-235
[18] Quinn CE, Casper RF. Pinopodes: 
A questionable role in endometrial 
receptivity. Human Reproduction 
Update. 2009;15(2):229-236
[19] Zhang T et al. The role of three-
dimensional power Doppler ultrasound 
parameters measured on hCG day in the 
prediction of pregnancy during in vitro 
References
19
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past, Present, and Future…
DOI: http://dx.doi.org/10.5772/intechopen.80452
fertilization treatment. European 
Journal of Obstetrics, Gynecology, and 
Reproductive Biology. 2016;203:66-71
[20] Abdalla HI et al. Endometrial 
thickness: A predictor of implantation 
in ovum recipients? Human 
Reproduction. 1994;9(2):363-365
[21] Yuval Y et al. The relationships 
between endometrial thickness, 
and blood flow and pregnancy rates 
in in-vitro fertilization. Human 
Reproduction. 1999;14(4):1067-1071
[22] Schild RL et al. Endometrial 
receptivity in an in vitro fertilization 
program as assessed by spiral artery blood 
flow, endometrial thickness, endometrial 
volume, and uterine artery blood flow. 
Fertility and Sterility. 2001;75(2):361-366
[23] Noyes N et al. Factors useful 
in predicting the success of oocyte 
donation: A 3-year retrospective 
analysis. Fertility and Sterility. 
2001;76(1):92-97
[24] Friedler S et al. The role of 
ultrasonography in the evaluation 
of endometrial receptivity following 
assisted reproductive treatments: A 
critical review. Human Reproduction 
Update. 1996;2(4):323-335
[25] Khalifa E et al. Sonographic 
appearance of the endometrium: The 
predictive value for the outcome of 
in-vitro fertilization in stimulated 
cycles. Human Reproduction. 
1992;7(5):677-680
[26] Sundström P. Establishment of a 
successful pregnancy following in-vitro 
fertilization with an endometrial 
thickness of no more than 4 mm. 
Human Reproduction (Oxford, 
England). 1998;13(6):1550-1552
[27] Remohi J et al. Endometrial 
thickness and serum oestradiol 
concentrations as predictors of 
outcome in oocyte donation. Human 
Reproduction (Oxford, England). 
1997;12(10):2271-2276
[28] Mercé LT. Ultrasound markers 
of implantation. The Ultrasound 
Review of Obstetrics and Gynecology. 
2002;2(2):110-123
[29] Raga F et al. Assessment of 
endometrial volume by three-
dimensional ultrasound prior to 
embryo transfer: Clues to endometrial 
receptivity. Human Reproduction. 
1999;14(11):2851-2854
[30] Zhao J, Zhang Q , Li Y. The effect 
of endometrial thickness and pattern 
measured by ultrasonography on 
pregnancy outcomes during IVF-ET 
cycles. Reproductive Biology and 
Endocrinology. 2012;10:100
[31] Zhao J et al. Endometrial pattern, 
thickness and growth in predicting 
pregnancy outcome following 3319 
IVF cycle. Reproductive Biomedicine 
Online. 2014;29(3):291-298
[32] Fatemi HM, Popovic-Todorovic 
B. Implantation in assisted 
reproduction: A look at endometrial 
receptivity. Reproductive Biomedicine 
Online. 2013;27(5):530-538
[33] Coulam CB, Jeyendran RS. Vascular 
endothelial growth factor gene 
polymorphisms and recurrent 
pregnancy loss. American Journal 
of Reproductive Immunology. 
2008;59(4):301-305
[34] Papazoglou D et al. Vascular 
endothelial growth factor gene 
polymorphisms and idiopathic 
recurrent pregnancy loss. Fertility and 
Sterility. 2005;83(4):959-963
[35] Lee HH et al. Association study 
of vascular endothelial growth 
factor polymorphisms with the 
risk of recurrent spontaneous 
abortion. Fertility and Sterility. 
2010;93(4):1244-1247
Modern Medical Genetics and Genomics
20
[36] Goodman C, Jeyendran RS, Coulam 
CB. Vascular endothelial growth factor 
gene polymorphism and implantation 
failure. Reproductive Biomedicine 
Online. 2008;16(5):720-723
[37] Goodman C, Jeyendran RS, Coulam 
CB. P53 tumor suppressor factor, 
plasminogen activator inhibitor, and 
vascular endothelial growth factor 
gene polymorphisms and recurrent 
implantation failure. Fertility and 
Sterility. 2009;92(2):494-498
[38] Xu X et al. Association of VEGF 
genetic polymorphisms with recurrent 
spontaneous abortion risk: A systematic 
review and meta-analysis. PLoS One. 
2015;10(4):e0123696
[39] Su MT, Lin SH, Chen YC. Genetic 
association studies of angiogenesis- and 
vasoconstriction-related genes in women 
with recurrent pregnancy loss: A systematic 
review and meta-analysis. Human 
Reproduction Update. 2011;17(6):803-812
[40] Kang HJ et al. Single-nucleotide 
polymorphisms in the p53 pathway 
regulate fertility in humans. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2009;106(24):9761-9766
[41] Coulam CB, Kay C, Jeyendran 
RS. Role of p53 codon 72 polymorphism 
in recurrent pregnancy loss. 
Reproductive Biomedicine Online. 
2006;12(3):378-382
[42] Yenicesu GI et al. A prospective 
case-control study analyzes 12 
thrombophilic gene mutations in 
Turkish couples with recurrent 
pregnancy loss. American Journal 
of Reproductive Immunology. 
2010;63(2):126-136
[43] Jia M, Dahlman-Wright K, 
Gustafsson JA. Estrogen receptor 
alpha and beta in health and disease. 
Best Practice & Research. Clinical 
Endocrinology & Metabolism. 
2015;29(4):557-568
[44] Yuan R, Le AW. A study on 
the estrogen receptor alpha gene 
polymorphism and its expression 
in thin endometrium of unknown 
etiology. Gynecologic and Obstetric 
Investigation. 2012;74(1):13-20
[45] Hey NA et al. The polymorphic 
epithelial mucin MUC1 in human 
endometrium is regulated with maximal 
expression in the implantation phase. 
The Journal of Clinical Endocrinology 
and Metabolism. 1994;78(2):337-342
[46] Xu B et al. Pinopodes, leukemia 
inhibitory factor, integrin-beta3, 
and mucin-1 expression in the 
peri-implantation endometrium of 
women with unexplained recurrent 
pregnancy loss. Fertility and Sterility. 
2012;98(2):389-395
[47] Meseguer M et al. Human 
endometrial mucin MUC1 is 
up-regulated by progesterone and 
down-regulated in vitro by the human 
blastocyst. Biology of Reproduction. 
2001;64(2):590-601
[48] Brayman M, Thathiah A, Carson 
DD. MUC1: A multifunctional cell 
surface component of reproductive 
tissue epithelia. Reproductive Biology 
and Endocrinology. 2004;2:4
[49] Carson DD, DeSouza MM, 
Regisford EG. Mucin and proteoglycan 
functions in embryo implantation. 
BioEssays. 1998;20(7):577-583
[50] Audie JP et al. Mucin 
gene expression in the human 
endocervix. Human Reproduction. 
1995;10(1):98-102
[51] Nollet S et al. Human mucin gene 
MUC4: Organization of its 5′-region 
and polymorphism of its central tandem 
repeat array. The Biochemical Journal. 
1998;332(Pt 3):739-748
[52] Ferrell AD et al. Sialomucin 
complex (Muc4) expression in porcine 
endometrium during the oestrous cycle 
21
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past, Present, and Future…
DOI: http://dx.doi.org/10.5772/intechopen.80452
and early pregnancy. Reproduction in 
Domestic Animals. 2003;38(1):63-65
[53] Carraway KL, Idris N. Regulation 
of sialomucin complex/Muc4 in 
the female rat reproductive tract. 
Biochemical Society Transactions. 
2001;29(Pt 2):162-166
[54] Coulam CB, Jeyendran R, Roussev 
R. Association of progesterone receptor 
polymorphisms with recurrent 
implantation failure after in vitro 
fertilization and embryo transfer. 
Journal of Assisted Reproduction and 
Genetics. 2008;25(4):119-122
[55] Salazar LA et al. Association 
of −765G>C polymorphism of the 
COX-2 gene with recurrent embryo 
implantation failure in Southern 
Chilean women. Clinica Chimica Acta. 
2010;411(21-22):1822-1824
[56] Wang D et al. DNA 
hypomethylation of the COX-2 
gene promoter is associated with 
up-regulation of its mRNA expression in 
eutopic endometrium of endometriosis. 
European Journal of Medical Research. 
2012;17:12
[57] Pihusch R et al. Thrombophilic gene 
mutations and recurrent spontaneous 
abortion: Prothrombin mutation 
increases the risk in the first trimester. 
American Journal of Reproductive 
Immunology. 2001;46(2):124-131
[58] Goodman CS et al. Which 
thrombophilic gene mutations are risk 
factors for recurrent pregnancy loss? 
American Journal of Reproductive 
Immunology. 2006;56(4):230-236
[59] Vacquier VD. Oogenesis: 
Developmental biology. Science. 
1985;229(4718):1078-1079
[60] Qublan HS et al. Acquired and 
inherited thrombophilia: Implication 
in recurrent IVF and embryo transfer 
failure. Human Reproduction. 
2006;21(10):2694-2698
[61] Haroun S et al. Association 
between trefoil factor 3 gene variants 
and idiopathic recurrent spontaneous 
abortion. Reproductive Biomedicine 
Online. 2014;29(6):737-744
[62] Singh M, Chaudhry P, Asselin 
E. Bridging endometrial receptivity 
and implantation: Network of 
hormones, cytokines, and growth 
factors. The Journal of Endocrinology. 
2011;210(1):5-14
[63] Croy BA et al. Decidual natural 
killer cells: Key regulators of placental 
development (a review). Journal 
of Reproductive Immunology. 
2002;57(1-2):151-168
[64] Abrahamsohn PA, Zorn 
TM. Implantation and decidualization 
in rodents. The Journal of Experimental 
Zoology. 1993;266(6):603-628
[65] Gleicher N, Kushnir VA, Barad 
DH. Redirecting reproductive immunology 
research toward pregnancy as a period 
of temporary immune tolerance. Journal 
of Assisted Reproduction and Genetics. 
2017;34(4):425-430
[66] Lash GE, Robson SC, Bulmer 
JN. Review: Functional role of uterine 
natural killer (uNK) cells in human 
early pregnancy decidua. Placenta. 
2010;31(Suppl):S87-S92
[67] Bulmer JN, Williams PJ, 
Lash GE. Immune cells in the 
placental bed. The International 
Journal of Developmental Biology. 
2010;54(2-3):281-294
[68] King A, Loke YW. Effect of IFN-
gamma and IFN-alpha on killing 
of human trophoblast by decidual 
LAK cells. Journal of Reproductive 
Immunology. 1993;23(1):51-62
[69] Dosiou C, Giudice LC. Natural 
killer cells in pregnancy and recurrent 
pregnancy loss: Endocrine and 
immunologic perspectives. Endocrine 
Reviews. 2005;26(1):44-62
Modern Medical Genetics and Genomics
22
[70] Koopman LA et al. Human decidual 
natural killer cells are a unique NK 
cell subset with immunomodulatory 
potential. The Journal of Experimental 
Medicine. 2003;198(8):1201-1212
[71] Rachmilewitz J et al. Negative 
regulation of T cell activation by 
placental protein 14 is mediated by the 
tyrosine phosphatase receptor CD45. 
The Journal of Biological Chemistry. 
2003;278(16):14059-14065
[72] Poole JA, Claman HN. Immunology 
of pregnancy. Clinical Reviews 
in Allergy & Immunology. 
2004;26(3):161-170
[73] Runić R et al. Apoptosis and Fas 
expression in human fetal Membranes1. 
The Journal of Clinical Endocrinology 
& Metabolism. 1998;83(2):660-666
[74] Aschkenazi S et al. Differential 
regulation and function of the Fas/Fas 
ligand system in human trophoblast 
Cells1. Biology of Reproduction. 
2002;66(6):1853-1861
[75] Saito S, Sasaki Y, Sakai M. CD4(+)
CD25high regulatory T cells in human 
pregnancy. Journal of Reproductive 
Immunology. 2005;65(2):111-120
[76] La Rocca C et al. The immunology 
of pregnancy: Regulatory T cells control 
maternal immune tolerance toward the 
fetus. Immunology Letters. 2014;162 
(1 Pt A):41-48
[77] Guerin LR, Prins JR, Robertson 
SA. Regulatory T-cells and immune 
tolerance in pregnancy: A new 
target for infertility treatment? 
Human Reproduction Update. 
2009;15(5):517-535
[78] Heitmann RJ et al. Maternal T 
regulatory cell depletion impairs 
embryo implantation which can be 
corrected with adoptive T regulatory 
cell transfer. Reproductive Sciences. 
2017;24(7):1014-1024
[79] Dimova T et al. Maternal Foxp3 
expressing CD4+ CD25+ and CD4+ CD25- 
regulatory T-cell populations are enriched 
in human early normal pregnancy 
decidua: A phenotypic study of paired 
decidual and peripheral blood samples. 
American Journal of Reproductive 
Immunology. 2011;66(Suppl 1):44-56
[80] Haiqi H, Yong Z, Yi L. Transcriptional 
regulation of Foxp3 in regulatory T cells. 
Immunobiology. 2011;216(6):678-685
[81] Jasper MJ, Tremellen KP, Robertson 
SA. Primary unexplained infertility 
is associated with reduced expression 
of the T-regulatory cell transcription 
factor Foxp3 in endometrial tissue. 
Molecular Human Reproduction. 
2006;12(5):301-308
[82] Betz AG. Tolerating pregnancy. 
Nature. 2012;490:47
[83] Weetman AP. The immunology of 
pregnancy. Thyroid. 1999;9(7):643-646
[84] Clark DA, Croitoru K. TH1/TH2,3 
imbalance due to cytokine-producing 
NK, gammadelta T and NK-gammadelta 
T cells in murine pregnancy decidua 
in success or failure of pregnancy. 
American Journal of Reproductive 
Immunology. 2001;45(5):257-265
[85] Saito S. Cytokine network at 
the feto-maternal interface. Journal 
of Reproductive Immunology. 
2000;47(2):87-103
[86] Szekeres-Bartho J. Immunological 
relationship between the mother and 
the fetus. International Reviews of 
Immunology. 2002;21(6):471-495
[87] Piccinni MP, Romagnani 
S. Regulation of fetal allograft survival 
by a hormone-controlled Th1- and Th2-
type cytokines. Immunologic Research. 
1996;15(2):141-150
[88] Piccinni MP et al. Role of hormone-
controlled Th1- and Th2-type cytokines 
23
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past, Present, and Future…
DOI: http://dx.doi.org/10.5772/intechopen.80452
in successful pregnancy. Journal of 
Neuroimmunology. 2000;109(1):30-33
[89] Szekeres-Bartho J, Wegmann 
TG. A progesterone-dependent 
immunomodulatory protein alters the 
Th1Th2 balance. Journal of Reproductive 
Immunology. 1996;31(1):81-95
[90] Daftary GS et al. Direct regulation of 
beta3-integrin subunit gene expression by 
HOXA10 in endometrial cells. Molecular 
Endocrinology. 2002;16(3):571-579
[91] Taylor HS et al. HOXA10 is 
expressed in response to sex steroids at 
the time of implantation in the human 
endometrium. The Journal of Clinical 
Investigation. 1998;101(7):1379-1384
[92] Kim JJ et al. Altered expression 
of HOXA10 in endometriosis: 
Potential role in decidualization. 
Molecular Human Reproduction. 
2007;13(5):323-332
[93] Ruiz-Alonso M, Blesa D, Simon 
C. The genomics of the human 
endometrium. Biochimica et Biophysica 
Acta. 2012;1822(12):1931-1942
[94] Sonderegger S, Pollheimer J, Knofler 
M. Wnt signalling in implantation, 
decidualisation and placental 
differentiation--review. Placenta. 
2010;31(10):839-847
[95] Troy PJ et al. Transcriptional 
repression of peri-implantation EMX2 
expression in mammalian reproduction 
by HOXA10. Molecular and Cellular 
Biology. 2003;23(1):1-13
[96] Germeyer A et al. Endometrial 
beta3 integrin profile reflects 
endometrial receptivity defects in 
women with unexplained recurrent 
pregnancy loss. Reproductive Biology 
and Endocrinology. 2014;12:53
[97] Fischer CP, Kayisili U, Taylor 
HS. HOXA10 expression is decreased 
in endometrium of women with 
adenomyosis. Fertility and Sterility. 
2011;95(3):1133-1136
[98] Cermik D, Selam B, Taylor 
HS. Regulation of HOXA-10 
expression by testosterone in vitro 
and in the endometrium of patients 
with polycystic ovary syndrome. The 
Journal of Clinical Endocrinology and 
Metabolism. 2003;88(1):238-243
[99] Szczepanska M et al. Expression 
of HOXA-10 and HOXA-11 in the 
endometria of women with idiopathic 
infertility. Folia Histochemica et 
Cytobiologica. 2011;49(1):111-118
[100] Lessey BA et al. Regulated 
expression of heparin-binding EGF-like 
growth factor (HB-EGF) in the human 
endometrium: A potential paracrine 
role during implantation. Molecular 
Reproduction and Development. 
2002;62(4):446-455
[101] Stavreus-Evers A et al. 
Co-existence of heparin-binding 
epidermal growth factor-like 
growth factor and pinopodes in 
human endometrium at the time 
of implantation. Molecular Human 
Reproduction. 2002;8(8):765-769
[102] Yoo HJ, Barlow DH, Mardon 
HJ. Temporal and spatial regulation 
of expression of heparin-binding 
epidermal growth factor-like growth 
factor in the human endometrium: 
A possible role in blastocyst 
implantation. Developmental Genetics. 
1997;21(1):102-108
[103] Birdsall MA et al. Expression of 
heparin-binding epidermal growth 
factor messenger RNA in the human 
endometrium. Molecular Human 
Reproduction. 1996;2(1):31-34
[104] Chobotova K et al. Heparin-
binding epidermal growth factor and its 
receptor ErbB4 mediate implantation of 
the human blastocyst. Mechanisms of 
Development. 2002;119(2):137-144
Modern Medical Genetics and Genomics
24
[105] Leach RE et al. Multiple roles for 
heparin-binding epidermal growth 
factor-like growth factor are suggested 
by its cell-specific expression during 
the human endometrial cycle and early 
placentation. The Journal of Clinical 
Endocrinology and Metabolism. 
1999;84(9):3355-3363
[106] Cullinan EB et al. Leukemia 
inhibitory factor (LIF) and LIF receptor 
expression in human endometrium 
suggests a potential autocrine/
paracrine function in regulating 
embryo implantation. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
1996;93(7):3115-3120
[107] Aghajanova L et al. Coexpression 
of pinopodes and leukemia inhibitory 
factor, as well as its receptor, in human 
endometrium. Fertility and Sterility. 
2003;79(Suppl 1):808-814
[108] Diaz-Gimeno P et al. A genomic 
diagnostic tool for human endometrial 
receptivity based on the transcriptomic 
signature. Fertility and Sterility. 
2011;95(1):50-60 60e1-15
[109] Guzeloglu-Kayisli O, Kayisli UA, 
Taylor HS. The role of growth factors 
and cytokines during implantation: 
Endocrine and paracrine interactions. 
Seminars in Reproductive Medicine. 
2009;27(1):62-79
[110] Lessey BA et al. Distribution 
of integrin cell adhesion molecules 
in endometrial cancer. The 
American Journal of Pathology. 
1995;146(3):717-726
[111] Steck T et al. Leukaemia inhibitory 
factor (LIF) gene mutations in women 
with unexplained infertility and 
recurrent failure of implantation 
after IVF and embryo transfer. 
European Journal of Obstetrics, 
Gynecology, and Reproductive Biology. 
2004;112(1):69-73
[112] Lessey BA et al. Integrin adhesion 
molecules in the human endometrium. 
Correlation with the normal and 
abnormal menstrual cycle. The 
Journal of Clinical Investigation. 
1992;90(1):188-195
[113] Lessey BA et al. Further 
characterization of endometrial 
integrins during the menstrual cycle 
and in pregnancy. Fertility and Sterility. 
1994;62(3):497-506
[114] Lessey BA et al. Integrins as 
markers of uterine receptivity in 
women with primary unexplained 
infertility. Fertility and Sterility. 
1995;63(3):535-542
[115] Dorostghoal M et al. Endometrial 
expression of beta3 integrin, calcitonin 
and plexin-B1 in the window 
of implantation in women with 
unexplained infertility. International 
Journal of Reproductive BioMedicine 
(Yazd, Iran). 2017;15(1):33-40
[116] von Wolff M et al. Endometrial 
osteopontin, a ligand of beta3-integrin, 
is maximally expressed around the time 
of the “implantation window”. Fertility 
and Sterility. 2001;76(4):775-781
[117] Carson DD et al. Changes in gene 
expression during the early to mid-
luteal (receptive phase) transition 
in human endometrium detected by 
high-density microarray screening. 
Molecular Human Reproduction. 
2002;8(9):871-879
[118] Ponnampalam AP et al. Molecular 
classification of human endometrial 
cycle stages by transcriptional profiling. 
Molecular Human Reproduction. 
2004;10(12):879-893
[119] Punyadeera C et al. Oestrogen-
modulated gene expression in the 
human endometrium. Cellular 
and Molecular Life Sciences. 
2005;62(2):239-250
25
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past, Present, and Future…
DOI: http://dx.doi.org/10.5772/intechopen.80452
[120] Talbi S et al. Molecular 
phenotyping of human endometrium 
distinguishes menstrual cycle 
phases and underlying biological 
processes in normo-ovulatory women. 
Endocrinology. 2006;147(3):1097-1121
[121] Bartel DP. MicroRNAs: Genomics, 
biogenesis, mechanism, and function. 
Cell. 2004;116(2):281-297
[122] Shukla GC, Singh J, Barik 
S. MicroRNAs: Processing, maturation, 
target recognition and regulatory 
functions. Molecular and Cellular 
Pharmacology. 2011;3(3):83-92
[123] Lim LP et al. Microarray 
analysis shows that some 
microRNAs downregulate large 
numbers of target mRNAs. Nature. 
2005;433(7027):769-773
[124] Lee RC, Feinbaum RL, Ambros 
V. The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense 
complementarity to lin-14. Cell. 
1993;75(5):843-854
[125] Weber JA et al. The microRNA 
spectrum in 12 body fluids. Clinical 
Chemistry. 2010;56(11):1733-1741
[126] Pogribny IP. MicroRNAs as 
biomarkers for clinical studies. 
Experimental Biology and Medicine 
(Maywood, NJ). 2018;243(3):283-290
[127] Pan Q , Chegini N. MicroRNA 
signature and regulatory functions in 
the endometrium during normal and 
disease states. Seminars in Reproductive 
Medicine. 2008;26(6):479-493
[128] Hull ML, Nisenblat V. Tissue 
and circulating microRNA influence 
reproductive function in endometrial 
disease. Reproductive Biomedicine 
Online. 2013;27(5):515-529
[129] Katzorke N et al. Diagnosis 
of endometrial-factor infertility: 
Current approaches and new avenues 
for research. Geburtshilfe und 
Frauenheilkunde. 2016;76(6):699-703
[130] Vilella F et al. Hsa-miR-30d, 
secreted by the human endometrium, 
is taken up by the pre-implantation 
embryo and might modify its 
transcriptome. Development. 
2015;142(18):3210-3221
[131] Cuman C et al. Human blastocyst 
secreted microRNA regulate 
endometrial epithelial cell adhesion. 
eBioMedicine. 2015;2(10):1528-1535
[132] Kuokkanen S et al. Genomic 
profiling of microRNAs and messenger 
RNAs reveals hormonal regulation 
in microRNA expression in human 
endometrium. Biology of Reproduction. 
2010;82(4):791-801
[133] Altmae S et al. MicroRNAs 
miR-30b, miR-30d, and miR-
494 regulate human endometrial 
receptivity. Reproductive Sciences. 
2013;20(3):308-317
[134] Revel A et al. MicroRNAs are 
associated with human embryo 
implantation defects. Human 
Reproduction. 2011;26(10):2830-2840
[135] Shi C et al. Endometrial MicroRNA 
signature during the window of 
implantation changed in patients with 
repeated implantation failure. Chinese 
Medical Journal. 2017;130(5):566-573
[136] Estella C et al. miRNA signature 
and dicer requirement during human 
endometrial stromal decidualization 
in vitro. PLoS One. 2012;7(7):e41080
[137] Zullo J et al. The cell secretome, a 
mediator of cell-to-cell communication. 
Prostaglandins & Other Lipid 
Mediators. 2015;120:17-20
[138] Casado-Vela J et al. 
Comprehensive proteomic analysis 
Modern Medical Genetics and Genomics
26
of human endometrial fluid aspirate. 
Journal of Proteome Research. 
2009;8(10):4622-4632
[139] Boomsma CM et al. Endometrial 
secretion analysis identifies a cytokine 
profile predictive of pregnancy 
in IVF. Human Reproduction. 
2009;24(6):1427-1435
[140] Demiral I et al. Genomic, 
proteomic and lipidomic evaluation 
of endometrial receptivity. Turkish 
Journal of Obstetrics and Gynecology. 
2015;12(4):237-243
[141] Berlanga O et al. How endometrial 
secretomics can help in predicting 
implantation. Placenta. 2011;32(Suppl 
3):S271-S275
[142] Vilella F, Ramirez LB, Simon 
C. Lipidomics as an emerging tool to 
predict endometrial receptivity. Fertility 
and Sterility. 2013;99(4):1100-1106
[143] Vilella F et al. PGE2 and PGF2alpha 
concentrations in human endometrial 
fluid as biomarkers for embryonic 
implantation. The Journal of Clinical 
Endocrinology and Metabolism. 
2013;98(10):4123-4132
[144] Peter Durairaj RR et al. 
Deregulation of the endometrial 
stromal cell secretome precedes embryo 
implantation failure. Molecular Human 
Reproduction. 2017;23(8):582
[145] Ansbacher R, Boyson WA, Morris 
JA. Sterility of the uterine cavity. 
American Journal of Obstetrics and 
Gynecology. 1967;99(3):394-396
[146] Perez-Munoz ME et al. A critical 
assessment of the “sterile womb” and 
“in utero colonization” hypotheses: 
Implications for research on the pioneer 
infant microbiome. Microbiome. 
2017;5(1):48
[147] Moreno I et al. Evidence that the 
endometrial microbiota has an effect 
on implantation success or failure. 
American Journal of Obstetrics and 
Gynecology. 2016;215(6):684-703
[148] Aagaard K et al. The placenta 
harbors a unique microbiome. 
Science Translational Medicine. 
2014;6(237):237ra65
[149] Verstraelen H et al. 
Characterisation of the human uterine 
microbiome in non-pregnant women 
through deep sequencing of the V1-2 
region of the 16S rRNA gene. Peer 
Journal. 2016;4:e1602
[150] Franasiak JM et al. Endometrial 
microbiome at the time of embryo 
transfer: Next-generation sequencing 
of the 16S ribosomal subunit. Journal 
of Assisted Reproduction and Genetics. 
2016;33(1):129-136
[151] Mitchell CM et al. Colonization 
of the upper genital tract by vaginal 
bacterial species in nonpregnant 
women. American Journal of Obstetrics 
and Gynecology. 2015;212(5):611.
e1-611.e9
[152] Moreno I, Franasiak 
JM. Endometrial microbiota-new 
player in town. Fertility and Sterility. 
2017;108(1):32-39
[153] Ravel J et al. Vaginal microbiome of 
reproductive-age women. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2011;108(Suppl 1):4680-4687
[154] Sha AG, Liu JL, Jiang XM, Ren 
JZ, Ma CH, Lei W, Su RW, Yang ZM. 
Genome-wide identification of micro-
ribonucleic acids associated with human 
endometrial receptivity in natural and 
stimulated cycles by deep sequencing. 
Fertil Steril. 2011;96(1):150-155 e155
